Inclusion Criteria:

- Age ≥ 18 years

- Histologically confirmed diagnosis of adenocarcinoma of the pancreas

- Locally advanced (non-resectable) or metastatic pancreatic cancer

- Presence of at least one uni-dimensional indicator lesion measurable by CT scan or
MRI in not an irradiated area (RECIST criteria)

- Immunohistochemical evidence or positive EGFR expression prior to study entry in
primary tumor and/or at least one metastasis

- Life expectancy of ≥ 3 months

- Karnofsky performance status of ≥70 at study entry

- Neutrophils ≥ 1.5 x 109/L, platelets ≥100 x 109/L, and hemoglobin ≥ 9 g/dL

- Bilirubin level either normal or < 1.5 x ULN

- ASAT and ALAT ≤ 2.5 X ULN (≤ 5 x ULN if liver metastasis are present)

- Serum creatinine < 1.5 x ULN

- Effective contraception for both, male and female patients if the risk of conception
exists

- Signed written informed consents prior to beginning protocol specific procedures

Exclusion Criteria:

- Brain metastasis

- Previous chemotherapy for locally advanced or metastatic pancreatic cancer

- Adjuvant therapy is allowed if recurrence is documented > 6 months after the end of
adjuvant treatment

- Radiotherapy within 4 weeks prior to study entry

- Concurrent chronic systemic immune therapy

- Any investigational agent(s) 4 weeks prior to entry

- Previous exposure to EGF, monoclonal antibodies, signal transduction inhibitors or
EGFR targeting therapy

- Clinically relevant coronary artery disease or a history of a myocardial infarction
within the last 12 months

- Known grade 3 or 4 allergic reaction to any of the components of the treatment

- Known drug abuse/ alcohol abuse

- Legal incapacity or limited legal capacity

- Medical or psychological condition which in the opinion of the investigator would not
permit the patient to complete the study or sign meaningful informed consent

- Women who are pregnant or breastfeeding

- Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ
of the cervix. (Patients with a previous malignancy but without evidence of disease
for ≥ 5 years will be allowed to enter the trial).